These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21410960)

  • 1. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study.
    Wade AG; Crawford GM; Yellowlees A
    BMC Psychiatry; 2011 Mar; 11():42. PubMed ID: 21410960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder.
    Kim EY; Kim SH; Lee HJ; Lee NY; Kim HY; Park CHK; Ahn YM
    J Affect Disord; 2019 Dec; 259():91-97. PubMed ID: 31445345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escitalopram in the long-term treatment of major depressive disorder.
    Wade A; Despiegel N; Heldbo Reines E
    Ann Clin Psychiatry; 2006; 18(2):83-9. PubMed ID: 16754413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
    Leuchter AF; Lesser IM; Trivedi MH; Rush AJ; Morris DW; Warden D; Fava M; Wisniewski SR; Luther JF; Perales M; Gaynes BN; Stewart JW
    J Psychiatr Pract; 2008 Sep; 14(5):271-80. PubMed ID: 18832958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
    Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
    Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
    Signorovitch J; Ramakrishnan K; Ben-Hamadi R; Yu AP; Wu EQ; Dworak H; Erder MH
    Curr Med Res Opin; 2011 Jun; 27(6):1089-96. PubMed ID: 21438794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting relapse in elderly patients with major depressive disorder treated with escitalopram in an outpatient setting.
    Dolberg O; Larsson Lönn S; Kvist K
    Curr Med Res Opin; 2014 Jul; 30(7):1301-7. PubMed ID: 24628498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
    Moore N; Verdoux H; Fantino B
    Int Clin Psychopharmacol; 2005 May; 20(3):131-7. PubMed ID: 15812262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.